Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide

Dworkin, Michael; Mehan, William A.; Niemierko, Andrzej; Kamran, Sophia C.; Lamba, Nayan; Dietrich, Jörg; Martinez‐Lage, Maria; Oh, Kevin; Batchelor, Tracy T.; Wen, Patrick Y.; Loeffler, Jay S.; Shih, Helen A.

doi:10.1007/s11060-018-03063-1

Cited by 40 publications

(29 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Van West et al [15] were the only study to report median (range) time to first PsP detection following IMRT, 12 (3-78) months. Dworkin et al [31] were the only study to report the same parameter following PBT, 8 (1-66) months.…”

Section: Pseudoprogression In the Adult Populationmentioning

confidence: 96%

“…After the removal of 214 duplicate articles, the title and abstract of the remaining 300 articles were evaluated against the selection criteria. Full-text analysis was performed for 18 articles, in which 9 retrospective observational cohort studies were assessed to satisfy all selection criteria for quantitative analysis, 5 studies [26][27][28][29][30] describing outcomes of pediatric LGG, and another 4 studies [15,[31][32][33] describing outcomes of adult LGG ( Table 1). Definitions of PsP by each study are included in Table 2.…”

Section: Search Strategymentioning

confidence: 99%

“…The 4 adult LGG studies [15,[31][32][33] described the PsP outcomes of 424 subjects, where 271 (64%) were treated with IMRT, and 153 (36%) were treated with PBT (Table 1). Median age ranged from 37 to 45 years old with proportion of female subjects ranging from 30% to 53% and median follow-up ranging from 0.5 to 6 years.…”

Section: Demographics and Clinical Features In The Adult Populationmentioning

confidence: 99%

“…3). In those treated by PBT (2 cohort studies [31,32]; n = 99 subjects), the incidence of PsP was estimated to be 30% (95% CI, 21-39%; I 2 = NA) by RE modelling. The incidence rate following IMRT was significantly lower than that following PBT (Pheterogeneity = 0.04).…”

Section: Pseudoprogression In the Adult Populationmentioning

confidence: 99%

See 3 more Smart Citations

Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis

Welby

Laack

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

Section: Pseudoprogression In the Adult Populationmentioning

confidence: 96%

Section: Search Strategymentioning

confidence: 99%

Section: Demographics and Clinical Features In The Adult Populationmentioning

confidence: 99%

Section: Pseudoprogression In the Adult Populationmentioning

confidence: 99%

See 2 more Smart Citations

Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis

Welby

Laack

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…Glioma, a malignant tumor, is the most common intracranial primary cancer with the highest morbidity and mortality rates worldwide [1][2][3][4]. In spite of the great efforts on the clinical development, the long-term prognosis and postoperative outcomes for patients are still far from being satisfactory [5,6]. Moreover, palliative therapies fail to achieve the desirable therapeutic efficiency in consideration of the vague understanding on the potential pathophysiological mechanisms of glioma progression [7].…”

Section: Introductionmentioning

confidence: 99%

Tumor-Suppressive Function of lncRNA-MEG3 in Glioma Cells by Regulating miR-6088/SMARCB1 Axis

Gong

Huang

2020

BioMed Research International

View full text Add to dashboard Cite

Objective. Mounting evidence has elaborated the implication of long noncoding RNAs (lncRNAs) in tumorigenesis of several cancers, including glioma. However, little was known about the mechanism of lncRNA maternally expressed gene 3 (MEG3) in the development and progression of glioma. This work is designed to explore the effect of MEG3 on glioma progression and its possible mechanism. Methods. Expressions of lncRNA-MEG3 and SMARCB1 were detected in human glioblastoma U87 and U251 cell lines. Gain and loss of function of MEG3 or/and miR-6088 was performed in U87 and U251 cells to observe its effect on cell proliferation and migration as well as on epithelial-mesenchymal transition (EMT) related markers. Luciferase reporter gene assay was employed to inspect the interactions among MEG3, miR-6088, and SMARCB1. Results. MEG3 and SMARCB1 expressions were downregulated in glioma cells. Transfection of pcDNA3.1-MEG3 or pcDNA3.1-SMARCB1 plasmids could clearly block cell proliferation, migration, and EMT progression. MEG3 functions as a sponge for miR-6088, while SMARCB1 is a downstream protein of miR-6088. Transfection of miR-6088 mimic or si-SMARCB1 could obviously reverse the favorable effect of pcDNA3.1-MEG3 on glioma progression. Conclusion. Collectively, the evidence in this study indicated that MEG3 was downregulated in glioma cells and inhibited proliferation and migration of glioma cells via regulating miR-6088/SMARCB1 axis.

show abstract

Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy

2021

View full text Add to dashboard Cite

Criteria by the Radiologic Assessment in Neuro-Oncology (RANO) group outline the diagnosis of pseudoprogression (Ps) after photon therapy for gliomas based on timing and location. We noted that patients receiving proton therapy manifested radiographic changes that appear different than Ps after photon therapy, which could be interpreted as tumor progression. In this study, we retrospectively reviewed MR imaging after proton or photon radiation for gliomas. We propose criteria to characterize proton pseudoprogression (ProPs) as distinct from Ps seen after photons. MethodsPost-treatment MR imaging, clinical and pathological data of low grade glioma patients were reviewed.Overall, 57 patients receiving protons were reviewed for the presence of ProPs, and 43 patients receiving photons were reviewed for any equivalent imaging changes. Data collected included the location and timing of the new enhancement, tumor grade, molecular subtype, chemotherapy received, and clinical symptoms. ResultsFourteen patients (24.6%) had new enhancement following radiation therapy that was unique to treatment with protons. The mean time to development of the ProPs was 15.4 months (7-27 months). We established the following criteria to characterize ProPs: located at the distal end of the proton beam; resolves without tumor-directed therapy; and subjectively multifocal, patchy, and small (< 1 cm). In the group receiving photons, none had changes that met our criteria for ProPs. ConclusionPatients who receive protons have unique imaging changes after radiation therapy. ProPs could be mistaken for tumor progression, but typically resolves on follow up. Further studies are needed to understand the radiobiology and pathophysiology underlying these imaging changes.

show abstract

Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide

Cited by 40 publications

References 49 publications

Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis

Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis

Tumor-Suppressive Function of lncRNA-MEG3 in Glioma Cells by Regulating miR-6088/SMARCB1 Axis

Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy

Contact Info

Product

Resources

About